Lessons learned from trends in psychotropic drug expenditures in a Canadian province

Carolyn S Dewa, P. Goering

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Although prescription drug prices are lower in Canada than in the United States, trends indicate that there has nevertheless been a steep increase in expenditures on psychotropic drugs. Between 1992 and 1998, such expenditures increased by 216 percent; 61 percent of these expenditures were on antidepressants, 33 percent on antipsychotics, and less than 7 percent on anxiolytics. Most of the increase in costs in Canada is attributable to a greater use of newer agents and the higher prices of these agents. These trends are a reminder not only that the use of newer, more expensive psychotherapeutic agents has become a widely embraced part of care but also that lower drug prices do not necessarily insulate a health care system from rising expenditures. The authors' findings prompt the questions of whether the use of these newer agents meets practice guidelines and whether there are ways to control the increases in drug expenditures while ensuring high-quality care.

Original languageEnglish (US)
Pages (from-to)1245-1247
Number of pages3
JournalPsychiatric Services
Volume52
Issue number9
DOIs
StatePublished - 2001
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Lessons learned from trends in psychotropic drug expenditures in a Canadian province'. Together they form a unique fingerprint.

Cite this